Compare DOMO & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | ATYR |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 79.2M |
| IPO Year | 2018 | 2015 |
| Metric | DOMO | ATYR |
|---|---|---|
| Price | $8.64 | $0.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $14.38 | $8.75 |
| AVG Volume (30 Days) | 1.0M | ★ 2.2M |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,002,000.00 | $190,000.00 |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $2.72 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.01 | $0.64 |
| 52 Week High | $18.49 | $7.29 |
| Indicator | DOMO | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 28.08 | 41.71 |
| Support Level | $8.43 | $0.70 |
| Resistance Level | $8.97 | $0.83 |
| Average True Range (ATR) | 0.55 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 6.90 | 26.75 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.